Teva, the world's biggest generic drug maker has blanket coverage in its presence especially in USA and Canada. The company with acquisitions before 2005 had managed to place itself in the European market of Italy. After the takeover of Barr in 2008 only which brought Teva, the European assets of Pliva (which Pliva took over form Merck), it has been the sole objective of this generic drug giant to strengthen its position in the largest European generics market of Germany.
Nothing could have been better than Ratiopharm takeover for Teva. With Global Majors like Pfizer and generic drug giant, Actavis in the fray for the Ratiopharm, the stakes for this acquisition were definitely higher.
The Market today
Yes the Generic drug market has only 7 major players now. This is after Teva took over Ratiopharm last week. With this strategic take over in the German geography, Teva will enjoy complete supremacy in the market. In 2009, Teva achieved roughly US $ 14 billion sales worldwide. With take over from Ratiopharm, Teva will enjoy complete supremacy with the addition US $2.3 billion in its 2009 sales. The total sales for Teva would now reach roughly around US$ 16.2 billion which will make it the unmatched leader in the global generic drug market over its next competitor which is Sandoz with worldwide sales of approximately US$ 8 billion. The third in sales is Mylan (Sales of US$ 5 billion) followed by Watson (US $ 2.8 billion) , Stada( US$ 2.2.billion) and Ranbaxy ( US$ 1.7 billion).